Santarus gives estimated expenses for FY13 The company sees license fees including a $5M expense for a success-based milestone assuming FDA acceptance for review of the Ruconest Biologics License Application. The company also sees research and development expenses of approximately $34M-$38M, and selling, general and administrative expenses of approximately $131M-$134M, which include an incremental estimated $38M-$40M investment associated with the sales force expansion of 85 sales representatives and promotional and other costs associated with the Uceris launch and Zegerid relaunch.
News For SNTS From The Last 14 Days
Check below for free stories on SNTS the last two weeks.
Subscribe for More Information
